Cost Curve

A New Health Affairs Forefront Piece Seeks to Reset the ‘Pharm-to-Table’ Conversation

And lawmaker talk of PBM reform has returned. Will action follow?

Brian Reid

Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

And doing the math on 340B rebate models suggests that pharma’s new approach to paying 340B discounts shouldn’t harm providers

Brian Reid

The Need-to-Know on a Slow News Day: More MFN Deals Are Coming, and Why Pharma Thinks the U.S./U.K. Trade Agreement Should Be a Model

Brian Reid

The U.K. Will Make Efforts to Boost Drug Prices in Return for the Elimination of U.S. Tariffs

And the pharm-to-table pricing of obesity medicines gets even more dizzying as Lilly cuts the price of Zepbound vials

Brian Reid

The Search for Clarity on the Differences Between IRA and MFN Prices for Ozempic and Wegovy

And an FDA official calls out ‘unique financial incentives for vaccine makers’

Brian Reid

Medicare Negotiated Prices Are Out for 15 More Drugs. Here’s What We Know

Brian Reid

Today Is Mostly a Day for Waiting

Still, links to ponder on CMS hospital payments, the price of gene therapies, and UK price negotiations

Brian Reid

The Universe of Direct-to-Business Obesity Options Continues to Expand

And more 340B stories than you can shake a stick at

Brian Reid

The Pharm-to-Conference-Table Trend Is Picking Up Steam

And a CMS advisor offers a peek behind the curtain on the agency’s myriad drug-pricing workstreams

Brian Reid